ArticleScientific reports2016
Limitations of MIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.American journal of respiratory and critical care medicine · 2021Trial
- Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic Escherichia coli.Nature communications · 2026Article
- Uncertainty undermines the validity of antimicrobial pharmacodynamics.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Phenotypic antimicrobial susceptibility and genomic resistance determinants in canine otitis-associatedFrontiers in veterinary science · 2026Article
- Simulation of a field condition to evaluate the risk of enrofloxacin-resistantFrontiers in veterinary science · 2025Article
- Context-dependent fitness benefits of antibiotic resistance mutations.Proceedings. Biological sciences · 2024Article
- Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.PLoS neglected tropical diseases · 2024Article
- Pharmacodynamic Model of the Dynamic Response ofBiomedicines · 2023Article
- The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution.Microbiology (Reading, England) · 2023Article
- Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.BMC microbiology · 2023Article
- Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools.Open forum infectious diseases · 2022Review
- Modelling the antimicrobial pharmacodynamics for bacterial strains with versus without acquired resistance to fluoroquinolones or cephalosporins.Journal of global antimicrobial resistance · 2022Article
- Low-Level Tolerance to Antibiotic Trimethoprim in QAC-Adapted Subpopulations ofFoods (Basel, Switzerland) · 2021Article
- Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.RSC medicinal chemistry · 2021Review
- Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward.Frontiers in pharmacology · 2021Review
- Exploring the Therapeutic Potenital of the Leaderless Enterocins K1 and EJ97 in the Treatment of Vancomycin-Resistant Enterococcal Infection.Frontiers in microbiology · 2021Article
- Pharmacokinetic and pharmacodynamic integration for optimal dosage of cefquinome against Streptococcus equi subsp. equi in foals.Veterinary research · 2020Article
- Antimicrobial Susceptibility Pattern of Porcine Respiratory Bacteria in Spain.Antibiotics (Basel, Switzerland) · 2020Article
- Quantitative Models of Phage-Antibiotic Combination Therapy.mSystems · 2020Article
- Resistance Evolution Against Antimicrobial Peptides inFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The minimum inhibitory concentration (MIC) of an antimicrobial drug for a bacterial pathogen is used as a measure of the bacterial susceptibility to the drug. However, relationships between the antimicrobial concentration, bacterial susceptibility, and the pharmacodynamic (PD) inhibitory effect on the bacterial population are more complex. The relationships can be captured by multi-parameter models such as the E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.